Stay updated on Nivolumab for Stage IIB-IIC Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Stage IIB-IIC Melanoma Clinical Trial page.
Latest updates to the Nivolumab for Stage IIB-IIC Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded an Outcome Measure: Number of Adverse Events and a new Last Update Posted (Estimated) field; removed the Incidence of adverse events and Last Update Posted fields.SummaryDifference0.4%
- Check20 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check28 days agoChange DetectedRemoved the government funding lapse notice from the page; the study details and eligibility information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check42 days agoChange DetectedNo substantive changes to the trial's endpoints, eligibility criteria, or locations; the update appears cosmetic (e.g., timestamp) and does not affect the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check71 days agoChange DetectedUpdated operating-status notice and version 3.2.0; removed version 3.1.0.SummaryDifference3%
- Check78 days agoChange DetectedAdded Melanoma as a topic and updated to revision v3.1.0; removed the older topic label Melanoma, Cutaneous Malignant and revision v3.0.2.SummaryDifference0.5%
Stay in the know with updates to Nivolumab for Stage IIB-IIC Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Stage IIB-IIC Melanoma Clinical Trial page.